News

Naropa University’s Center for Psychedelic Studies has become an independent entity, the Memoru Center for Visionary Healing Arts, in...

LIB Therapeutics has submitted a Biologics License Application (BLA) to the U.S. FDA for Lerodalcibep, a novel PCSK9 inhibitor...

Contineum Therapeutics has initiated a Phase 1b positron emission tomography (PET) trial for PIPE-791, a novel brain-penetrant, small molecule...

BeiGene, soon to be BeOne Medicines, has secured global licensing rights for SYH2039, a novel MAT2A inhibitor, from CSPC....

Bicycle Therapeutics presented data at the 2024 San Antonio Breast Conference Symposium (SABCS) highlighting the enhanced anti-tumor activity of...

Repare Therapeutics announced positive data from its Phase 1 MYTHIC trial combining lunresertib and camonsertib (Lunre+Camo) in patients with...

Corcept Therapeutics’ Phase 4 CATALYST study demonstrated that Korlym® significantly improved blood sugar control in patients with both Cushing’s...

Tobevibart and elebsiran, developed by Vir Biotechnology for chronic hepatitis delta (CHD), have received Breakthrough Therapy designation from the...

Atropos Health launched AI model training on its Atropos Evidence Network, a federated healthcare data network containing over 300...

Menarini Group, along with its subsidiary Stemline Therapeutics and research partner MEDSIR, presented research at the San Antonio Breast...